PMID- 38122916
OWN - NLM
STAT- MEDLINE
DCOM- 20240206
LR  - 20240206
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 194
DP  - 2024 Feb
TI  - Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with 
      FRa positive expression: A systematic review and meta-analysis.
PG  - 104230
LID - S1040-8428(23)00318-9 [pii]
LID - 10.1016/j.critrevonc.2023.104230 [doi]
AB  - OBJECTIVE: To evaluate the efficacy and safety of mirvetuximab soravtansine in 
      treating recurrent ovarian cancer with folate receptor alpha (FRa) expression. 
      METHODS: A comprehensive search was conducted on online databases, including 
      PubMed, Cochrane Library, and EMBASE, to identify relevant literature about the 
      efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with 
      FRa-positive expression. The keywords were the following: recurrent ovarian 
      cancer, mirvetuximab soravtansine, FRa, and antibody-drug conjugate. Furthermore, 
      studies that satisfied the necessary qualifications were carefully evaluated for 
      further meta-analysis. RESULTS: This meta-analysis involved the examination of 
      seven trials with a total of 631 patients. According to the pooled data, the 
      objective response rate (ORR) was 36% (95%CI: 27%-45%). Similarly, the disease 
      control rate (DCR) was 88% (95% CI: 84-91%). Furthermore, the median 
      progression-free survival (PFS) was determined to be 6.1 months (95% CI: 
      4.27-7.47). The overall response rate and PFS for platinum-resistant ovarian 
      cancer were found to be 29% (95% CI: 25-32%) and 6.26 months (95% CI: 4.67-7.85), 
      respectively. The most often observed adverse events (AEs) in patients with 
      recurrent ovarian cancer (OC) receiving mirvetuximab soravtansine were blurred 
      vision (all grades: 45%, Grade III: 2%), nausea (all grades: 42%, Grade III: 1%), 
      and diarrhea (all grades: 42%, Grade III: 2%). These AEs were specifically 
      associated with the safety profile of mirvetuximab soravtansine in this patient 
      population. CONCLUSION: The efficacy of mirvetuximab soravtansine in treating 
      recurrent ovarian cancer with FRa-positive expression is satisfactory, and the 
      safety is tolerable.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Wang, Yicong
AU  - Wang Y
AD  - Department of Obstetrics and Gynecology,Central Hospital of Dalian University of 
      Technology, Dalian, China.
FAU - Liu, Lifeng
AU  - Liu L
AD  - Department of Obstetrics and Gynecology,Central Hospital of Dalian University of 
      Technology, Dalian, China.
FAU - Jin, Xianyu
AU  - Jin X
AD  - Department of Obstetrics and Gynecology,Central Hospital of Dalian University of 
      Technology, Dalian, China.
FAU - Yu, Yongai
AU  - Yu Y
AD  - Department of Obstetrics and Gynecology,Central Hospital of Dalian University of 
      Technology, Dalian, China. Electronic address: yongai1998@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20231218
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 98DE7VN88D (mirvetuximab soravtansine)
RN  - 0 (Immunoconjugates)
RN  - 14083FR882 (Maytansine)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Ovarian Neoplasms/drug therapy
MH  - Drug Resistance, Neoplasm
MH  - Carcinoma, Ovarian Epithelial/drug therapy
MH  - *Immunoconjugates/adverse effects
MH  - *Maytansine/analogs & derivatives
MH  - *Antibodies, Monoclonal, Humanized
OTO - NOTNLM
OT  - Antibody-drug conjugate (ADC)
OT  - Folate receptor alpha (FRa)
OT  - Mirvetuximab Soravtansine(MIRV)
OT  - Ovarian cancer(OC)
COIS- Declaration of Competing Interest The authors declare that there is no conflict 
      of interest in the publication of this paper.
EDAT- 2023/12/21 00:41
MHDA- 2024/02/06 06:42
CRDT- 2023/12/20 19:28
PHST- 2023/09/20 00:00 [received]
PHST- 2023/11/18 00:00 [revised]
PHST- 2023/12/05 00:00 [accepted]
PHST- 2024/02/06 06:42 [medline]
PHST- 2023/12/21 00:41 [pubmed]
PHST- 2023/12/20 19:28 [entrez]
AID - S1040-8428(23)00318-9 [pii]
AID - 10.1016/j.critrevonc.2023.104230 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2024 Feb;194:104230. doi: 
      10.1016/j.critrevonc.2023.104230. Epub 2023 Dec 18.